{"id":21536,"date":"2023-12-11T10:20:13","date_gmt":"2023-12-11T09:20:13","guid":{"rendered":"https:\/\/ggba.swiss\/diatheris-to-spearhead-a-new-era-in-type-1-diabetes-management\/"},"modified":"2023-12-11T10:23:20","modified_gmt":"2023-12-11T09:23:20","slug":"diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/","title":{"rendered":"Diatheris ouvre une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1"},"content":{"rendered":"\n<p>Fond\u00e9e sur les recherches innovantes de Giorgio Ramadori du <a href=\"https:\/\/www.unige.ch\/medecine\/phym\/fr\/accueil\">D\u00e9partement de physiologie cellulaire et m\u00e9tabolisme<\/a> de l&rsquo;UNIGE et du <a href=\"https:\/\/www.unige.ch\/medecine\/diabetescentre\/\">Centre facultaire du diab\u00e8te<\/a>, Diatheris est \u00e0 l&rsquo;avant-garde d&rsquo;une perc\u00e9e m\u00e9dicale majeure. Les recherches de Ramadori, qui s&rsquo;\u00e9tendent sur plus d&rsquo;une d\u00e9cennie, aboutissent au d\u00e9veloppement d&rsquo;une nouvelle strat\u00e9gie de traitement impliquant la prot\u00e9ine S100A9. Cette prot\u00e9ine s&rsquo;est r\u00e9v\u00e9l\u00e9e prometteuse pour prolonger la vie et am\u00e9liorer les marqueurs de sant\u00e9 chez les souris d\u00e9ficientes en insuline, ouvrant la voie \u00e0 des applications transformatrices chez l&rsquo;homme.<\/p>\n\n\n\n<p>L&rsquo;approche de <a href=\"https:\/\/www.diatheris.com\/\">Diatheris<\/a> se concentre sur l&rsquo;injection sous-cutan\u00e9e d&rsquo;une forme recombinante de S100A9. Ce traitement vise \u00e0 offrir une alternative plus s\u00fbre, plus efficace et moins restrictive aux th\u00e9rapies traditionnelles \u00e0 base d&rsquo;insuline. Les avantages potentiels sont consid\u00e9rables, promettant de r\u00e9duire la d\u00e9pendance \u00e0 l&rsquo;insuline tout en att\u00e9nuant les risques associ\u00e9s \u00e0 l&rsquo;hypoglyc\u00e9mie et \u00e0 l&rsquo;acidoc\u00e9tose diab\u00e9tique &#8211; des probl\u00e8mes courants et graves dans les traitements actuels du diab\u00e8te.<\/p>\n\n\n\n<p>La bourse du Helmsley Charitable Trust permettra \u00e0 Diatheris d&rsquo;achever des \u00e9tudes pr\u00e9cliniques essentielles et d&rsquo;ouvrir la voie \u00e0 des applications d&rsquo;essais cliniques d&rsquo;ici \u00e0 2025. Cette \u00e9tape marque un progr\u00e8s significatif dans le parcours de la start-up, soulignant un engagement commun \u00e0 am\u00e9liorer les connaissances m\u00e9dicales et la vie des personnes touch\u00e9es par le diab\u00e8te de type 1.<\/p>\n\n\n\n<p>Outre le <a href=\"https:\/\/helmsleytrust.org\/\">Helmsley Charitable Trust<\/a>, Diatheris a obtenu le soutien de diverses entit\u00e9s, notamment une bourse d&rsquo;<a href=\"https:\/\/www.innosuisse.ch\/inno\/fr\/home.html\">Innosuisse<\/a>, un financement de <a href=\"https:\/\/www.venturekick.ch\/fr\">Venture Kick<\/a> et le soutien de la <a href=\"https:\/\/www.fongit.ch\/fr\">FONGIT<\/a>. Ces soutiens soulignent non seulement le potentiel de la start-up, mais refl\u00e8tent \u00e9galement l&rsquo;engagement plus large en faveur de solutions m\u00e9dicales innovantes au sein de l&rsquo;\u00e9cosyst\u00e8me suisse des soins de sant\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diatheris, une start-up issue de l&rsquo;Universit\u00e9 de Gen\u00e8ve (UNIGE), a fait un bond prometteur dans le domaine du traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions accord\u00e9e par le Helmsley Charitable Trust.<\/p>\n","protected":false},"author":6,"featured_media":21532,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1162,1148,1188,1141,1142],"class_list":["post-21536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-education-en-fr","tag-financing-fr-2","tag-healthcare-fr-2","tag-personalized-medicine-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1<\/title>\n<meta name=\"description\" content=\"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1\" \/>\n<meta property=\"og:description\" content=\"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-11T09:20:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-11T09:23:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Diatheris ouvre une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1\",\"datePublished\":\"2023-12-11T09:20:13+00:00\",\"dateModified\":\"2023-12-11T09:23:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\"},\"wordCount\":333,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png\",\"keywords\":[\"Education\",\"Financing\",\"Healthcare\",\"Personalized Medicine\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\",\"name\":\"Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png\",\"datePublished\":\"2023-12-11T09:20:13+00:00\",\"dateModified\":\"2023-12-11T09:23:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Ce financement important soutient les efforts de Diatheris pour r\u00e9volutionner la gestion du diab\u00e8te de type 1 gr\u00e2ce \u00e0 des m\u00e9thodologies de traitement innovantes (de gauche \u00e0 droite : Pr. Roberto Coppari et Dr Giorgio Rimadori). | \u00a9 Diatheris\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diatheris ouvre une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1","description":"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/","og_locale":"fr_FR","og_type":"article","og_title":"Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1","og_description":"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.","og_url":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-12-11T09:20:13+00:00","article_modified_time":"2023-12-11T09:23:20+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Diatheris ouvre une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1","datePublished":"2023-12-11T09:20:13+00:00","dateModified":"2023-12-11T09:23:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/"},"wordCount":333,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png","keywords":["Education","Financing","Healthcare","Personalized Medicine","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/","url":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/","name":"Une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png","datePublished":"2023-12-11T09:20:13+00:00","dateModified":"2023-12-11T09:23:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Diatheris a fait un bond prometteur dans le traitement du diab\u00e8te gr\u00e2ce \u00e0 une bourse de CHF 2,5 millions du Helmsley Charitable Trust.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/Diatheris-1180x811-1.png","width":1180,"height":811,"caption":"Ce financement important soutient les efforts de Diatheris pour r\u00e9volutionner la gestion du diab\u00e8te de type 1 gr\u00e2ce \u00e0 des m\u00e9thodologies de traitement innovantes (de gauche \u00e0 droite : Pr. Roberto Coppari et Dr Giorgio Rimadori). | \u00a9 Diatheris"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/diatheris-ouvre-une-nouvelle-ere-dans-la-gestion-du-diabete-de-type-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Diatheris ouvre une nouvelle \u00e8re dans la gestion du diab\u00e8te de type 1"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=21536"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21536\/revisions"}],"predecessor-version":[{"id":21538,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21536\/revisions\/21538"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/21532"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=21536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=21536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=21536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}